Novartis AG agreed to acquire AveXis Inc for US$8.7 billion to gain a promising drug to treat a rare disease that afflicts infants, hastening a shift toward gene therapy and precision medicines.
Shareholders of the Bannockburn, Illinois-based company would receive US$218 a share in cash in a tender offer, Novartis said in a statement yesterday.
The price is 88 percent above where AveXis closed on Friday.
The transaction is Novartis’ second deal to advance in gene therapy this year — and the first led by new chief executive officer Vas Narasimhan.
The Swiss drugmaker is redeploying some of the US$13 billion in proceeds from the sale of its stake in a consumer-health joint venture to partner GlaxoSmithKline PLC to gain more firepower in prescription medicines before some of its existing best-sellers lose patent protection.
“Our goal is to build on a core of medicines as a medicines company powered by data and digital,” Narasimhan said in a conference call with investors. “A deal like this fits right in that sweet spot.”
AveXis is developing a product to treat spinal muscular atrophy, an inherited neurodegenerative disease caused by a defect in a single gene, which shows the potential to become a blockbuster, a Novartis statement said.
In buying AveXis, the Swiss drugmaker is also gaining the company’s AVXS-101 product to address a rare disease. Like gene therapies, such treatments command high prices that have sparked interest even from unexpected players in the industry.
AveXis also has valuable manufacturing and research capabilities that would give its Swiss buyer a platform alongside its research on chimeric antigen receptor T-cell therapy (CAR-T) in cancer “to advance a growing pipeline of gene therapies across therapeutic areas,” Narasimhan said.
Novartis’ Kymriah won US regulatory approval in August last year, making it the first drug approved from a new class of treatments called CAR-Ts that have been heralded as a promising approach to treating and potentially curing cancers as well as genetic conditions such as blindness. Like other gene therapies, it is used only once on a patient, and thus carries a high price tag — US$475,000, in the case of Kymriah.
AVXS-101 helped a small group of babies with spinal muscular atrophy hit development milestones at a rate previously unseen, a study showed in November last year.
The first medication for the disease, Biogen Inc’s Spinraza, won approval less than a year ago. Babies with the most severe form of the disease typically die before age two.
“This acquisition makes strategic sense,” Vontobel AG analyst Stefan Schneider wrote in a note to clients.
Novartis’ drugs Gilenya and Afinitor would probably face competition from cheaper generics next year — about the same time that AveXis’ first experimental drug might reach the market, Schneider said.
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Huawei Technologies Co’s (華為) latest smartphones carry a version of the advanced made-in-China processor it revealed last year, results from an independent analysis showed. This underscored the Chinese company’s ability to sustain production of the controversial chip. The Pura 70 series unveiled last week sports the Kirin 9010 processor, research firm TechInsights found during a teardown of the device. This is a newer version of the Kirin 9000s, made by Semiconductor Manufacturing International Corp (SMIC, 中芯) for the Mate 60 Pro, which had alarmed officials in Washington who thought a 7-nanometer chip was beyond China’s capabilities. Huawei has enjoyed a resurgence since
purpose: Tesla’s CEO sought to meet senior Chinese officials to discuss the rollout of its ‘full self-driving’ software in China and approval to transfer data they had collected Tesla Inc CEO Elon Musk arrived in Beijing yesterday on an unannounced visit, where he is expected to meet senior officials to discuss the rollout of "full self-driving" (FSD) software and permission to transfer data overseas, according to a person with knowledge of the matter. Chinese state media reported that he met Premier Li Qiang (李強) in Beijing, during which Li told Musk that Tesla's development in China could be regarded as a successful example of US-China economic and trade cooperation. Musk confirmed his meeting with the premier yesterday with a post on social media platform X. "Honored to meet with Premier Li